OncClub

Articles

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma

November 1st 2021

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

Landgren Lauds Promise of Carfilzomib Quadruplet Regimen in Newly Diagnosed Myeloma

June 16th 2021

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

Podcasts

Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers

July 29th 2021

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer

June 24th 2021

Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.

Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma

May 31st 2021

Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.